3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Mature B-cell Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Interventions
Cyclophosphamide
15
fludarabine
12
Mycophenolic Acid
10
Standard of Care
9
Whole-Body Irradiation
7
Tacrolimus
7
venetoclax
6
Specimen Handling
6
Sirolimus
6
Practice Guidelines as Topic
6
trametinib
5
Melphalan
5
fludarabine phosphate
4
Mesna
4
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Biopsy
4
Behavior Therapy
4
Azacitidine
4
Thiotepa
3
Peripheral Blood Stem Cell Transplantation
3
GSK2636771
3
Educational Status
3
Crizotinib
3
Busulfan
3
thymoglobulin
2
talquetamab
2
ruxolitinib
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
ARQ531
×
90 days
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled
NCT05347225
2026-04-30
MK-1026-005
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
12 enrolled